CD274 and hepatocellular carcinoma: The introduction of atezolizumab, a programmed cell death-ligand 1 (PD-L1) inhibitor, combined with bevacizumab, an anti-vascular endothelial growth factor, has significantly improved survival outcomes in patients with advanced HCC (4).